DiaSorin S.p.A. (LON:0GZX)

Market Cap	4.54B
Revenue (ttm)	980.31M
Net Income (ttm)	155.56M
Shares Out	n/a
EPS (ttm)	2.78
PE Ratio	29.20
Forward PE	n/a
Dividend	0.98 (1.01%)
Ex-Dividend Date	May 19, 2025

Volume	1,287
Average Volume	8,791
Open	97.58
Previous Close	97.60
Day's Range	95.60 - 97.82
52-Week Range	63.15 - 92.85
Beta	0.40
RSI	59.43
Earnings Date	May 6, 2025

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1968
• Employees: 3,308
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GZX

Financial Performance

In 2024, DiaSorin's revenue was 1.19 billion, an increase of 3.24% compared to the previous year's 1.15 billion. Earnings were 188.11 million, an increase of 17.68%.

Financial numbers in EUR